New VC firm seeks start-ups who are working to solve the “urgent problems” facing today’s aging society.
This summer, a new venture capital firm was...
Blood-based therapy developer to be 100% acquired by existing investor.
Longevity-focused biopharma firm Alkahest, which is developing therapies derived from blood, is to be acquired...
Health start-up Biofourmis, which leverages AI for personalised healthcare monitoring, has raised $100m from SoftBank.
SoftBank Group has led a $100m investment in Biofourmis, the...
Hong Kong public company enters Longevity business by acquiring aging clock specialist Deep Longevity.
Not even two months after it exited stealth to announce its...
We speak to the co-founder of Molecule about building a unique marketplace for early stage therapeutic development.
Next week (September 1 - 4), the annual...
Longevity Investors Conference aims to focus the investment spotlight on developments in anti-aging science.
As Greg Bailey told us last week: "When I was talking...
AgeTech Accelerator's Lorraine Morley on market disconnect, helping investors take the plunge and shaping the AgeTech market.
Continuing our series of interviews with our Advisory Panel...
Jinfiniti raising $5m as it prepares to launch new biomarkers test panel that measures genomic instability, epigenetic alteration, inflammation, cellular senescence, oxidative stress, tissue...
Juvenescence's Greg Bailey on democratising healthcare, paradigm shifts and disruptive technologies.
Yesterday we published the first part of our interview with Greg Bailey, CEO of...
Juvenescence's Greg Bailey on transformative scientific opportunities, immuno-resilience, modifying aging and funding.
Continuing our series of interviews with our Advisory Panel members, we spoke to Greg...
We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress.
Lifespan.io is a US-based non-profit organisation that seeks to...
Longevity International’s Tina Woods discusses how Covid-19 has catapulted health to the top of the global agenda.
Tina Woods is CEO and co-founder of Longevity...
We speak to the director of the Wake Forest Institute of Regenerative Medicine – a research organisation with a clear focus on commercialisation.
Just on...
Omega Therapeutics secures $85m to carry out clinical trials into epigenetic treatments for five key disease areas – and potentially for Covid-19.
While you might...
Company spawned by London start-up generator targets middle-aged recreational athletes with exoskeleton leggings powered by soft robotics.
Back in November, we brought you the story...
SENS Research Foundation's Aubrey de Grey on increasing investor appetites and the elephant in the Longevity room.
Continuing our series of interviews with our Advisory Panel...
University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology.
Deep in the labs at the...
Professor João Pedro de Magalhães on different areas of Longevity.
Continuing our series of interviews with our Advisory Panel members, we caught up with João Pedro...
Tom Britton joins Advisory Panel as plans for Longevity equity funding platform take another step forward.
Longevity.Technology: Just last month we announced the formation of...
Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug.
Already well-known for its beer and bureaucracy to its...
Scientists believe they may have made a significant leap forward in the fight against Parkinson’s disease with the discovery of cells which could help...
Dr Oliver Zolman makes the case for Longevity companies adopting a checklist when it comes to making anti-aging claims.
When it comes to marketing in...
A new report suggests that studying the relationship between interferons and senescence could be key to developing new anti-aging therapies.
There are some things which...
